Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06453824 · ClinicalTrials.gov registry record · Phase 1
SAD Evaluation of Safety, Tolerability, PK, and PD of MDI-2517 in Healthy Participants
A Phase 1 study, sponsored by MDI Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT06453824 is a Phase 1 study that has completed, run by MDI Therapeutics. The registered enrollment target is 48 participants.
The verdict
NCT06453824, a Phase 1 study, has completed, sponsored by MDI Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This is a Phase 1 study to test the safety and drug effects of MDI-2517 when given once in healthy volunteers.
Interventions
- OTHER Placebo
- DRUG MDI-2517
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2024-05-17 |
| Est. Completion | 2024-11-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06453824
The ClinicalTrials.gov registry entry for NCT06453824 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MDI Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06453824 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06453824 about?
NCT06453824 is a clinical study titled "SAD Evaluation of Safety, Tolerability, PK, and PD of MDI-2517 in Healthy Participants". This is a Phase 1 study to test the safety and drug effects of MDI-2517 when given once in healthy volunteers.
What is the current status of trial NCT06453824?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2024-05-17. Estimated completion is 2024-11-11.
What interventions are being tested in trial NCT06453824?
The interventions under investigation include: Placebo (OTHER), MDI-2517 (DRUG).
Who is sponsoring clinical trial NCT06453824?
This trial is sponsored by MDI Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.